Skip to main content
    C

    Castle Biosciences Inc (CSTL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $33.79
    -0.71 (-2.06%)

    Market Cap: $1.04B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Castle Biosciences Inc (CSTL) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Castle Biosciences (CSTL) trades at 2.7x sales and 2.2x book value. Its P/S of 2.7x is in line with its 5-year median.

    Current Multiples

    Its free cash flow yield is 0.4%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales2.7x
    Price to book2.2x
    Price to FCF261.2x
    EV/FCF244.1x
    PEGN/A
    FCF yield0.4%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S2.7x2.7xN/A
    P/B2.2x1.6xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 7 year ends shown, its P/S ranged from 2.3x in 2024 to 20.7x in 2020.

    Year endPriceP/EP/SP/B
    2025$38.90N/A3.3x2.4x
    2024$26.6543.0x2.3x1.8x
    2023$21.58N/A2.6x1.5x
    2022$23.54N/A4.5x1.6x
    2021$42.87N/A11.5x2.6x
    2020$67.15N/A20.7x3.4x
    2019$34.37N/A4.3x7.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CSTL

    Is CSTL stock overvalued?

    GNG's valuation label for CSTL is Overvalued.

    What is CSTL's price to sales ratio?

    Castle Biosciences has a price to sales ratio of 2.7x.